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A B S T R A C T
Objectives: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer. Androgen
receptor (AR) (96%) and HER2 (29–46%) expression, and a high propensity for regional lymph node metastases
are hallmarks of the disease. We hypothesized that c-MET, E-cadherin, PSMA tumor and PSMA neovascular
expression may be prognostic factors in SDC.
Materials and methods: Expression levels of these proteins were established on tissue microarrays containing 165
primary SDC tumor specimens. Association with survival was studied with Kaplan-Meier curves, and univariable
and multivariable Cox regression models. Furthermore, association with lymph node status, AR and HER2 ex-
pression, and gender was studied.
Results: We found that patients with high PSMA tumor expression showed a significantly longer overall survival
(OS) (median 83 vs. 43months, P= 0.022), a trend towards a longer DFS (median 51 vs. 22months, P=0.094),
and significantly reduced hazard ratio for death in the univariable Cox regression model (HR 0.46, P=0.034).
In the multivariable model only a high number of tumor-positive lymph nodes and high age (> 80) at diagnosis
were prognostic for poor OS. High PSMA tumor expression was also significantly associated with low N-stage
(P= 0.001) and expression was higher in women versus men (P= 0.029). High PSMA tumor expression and E-
cadherin loss were significantly associated with strong and weak AR-expression, respectively (P= 0.033 and
P=0.007). None of the factors were significantly associated with HER2 expression.
Conclusion: c-MET, E-cadherin, and tumor and neovascular PSMA expression are no independent prognostic
factors in SDC.
Introduction
Salivary duct carcinoma (SDC) is an aggressive subtype of salivary
gland cancer (SGC) with a median overall survival (OS) of 3–5 years
after primary diagnosis [1–4]. Primary treatment of SDC consists of
tumor resection, most often in combination with a neck dissection and
postoperative radiotherapy. Despite this extensive primary treatment,
the recurrence risk is high with a 3-year disease-free survival of only
27.7% in patients presenting with more than 1 regional lymph node
metastasis [5]. Better knowledge of prognostic factors is needed to in-
crease our understanding of the pathogenesis of SDC and to guide
treatment decisions.
Androgen receptor (AR) and human epidermal growth factor re-
ceptor 2 (HER2) expression are key tumor characteristics of SDC, but
these are no prognostic factors [1]. Virtually all SDCs are AR-positive
(96% in our cohort after expert pathology review) [1], and androgen
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deprivation therapy (ADT) is often used as first-line palliative treatment
with a response rate of 41.7%, median progression-free survival (PFS)
of 8.8 months and low toxicity in a prospective phase 2 trial in 36 pa-
tients [6]. HER2 overexpression is seen in 29–46% of SDCs [1,7,8] and
these patients can be treated with HER2 targeted therapy. Docetaxel
plus trastuzumab showed a response rate of 70.2% and median pro-
gression-free survival of 9months in a prospective phase 2 trial in 57
patients with HER2 overexpression [9]. Trastuzumab-emtansine
showed a response rate of 90% in 10 SDC patients treated in a basket
trial and can also be used as HER2-targeted therapy [10].
A striking clinical feature of SDC is the high propensity for lymph
node metastases. At disease presentation, 47–68% of patients are di-
agnosed with lymph node metastases, and often an abundancy of lymph
node metastases (median 4, range 0–97) are observed in the neck dis-
section specimen [1,11,12]. We previously showed that the absolute
number of tumor-positive lymph nodes in the neck dissection is a
prognostic factor in a multivariable Cox regression analysis [1]. The
cause of the high number of lymph node metastases in SDC remains
elusive.
We hypothesized that c-MET expression or E-cadherin loss may be
associated with the high propensity for lymph node metastases and may
be prognostic factors. c-MET is a receptor tyrosine kinase which can be
activated by binding of hepatocyte growth factor (HGF). Activation of
the HGF/MET pathway promotes cell proliferation, survival, migration,
and invasion [13–16]. c-MET expression was observed in 50% of 28
SDCs in a Korean cohort [17]. The prognostic value of c-MET for sur-
vival and its association with lymph node metastases is unclear, al-
though genetic MET aberrations were a significant predictor for lymph
node metastases in a cohort of 316 SGC cases, including 35 SDCs [18].
Epithelial cadherin (E-cadherin) is a cell-cell adhesion molecule. Loss of
E-cadherin is involved in cancer invasion and metastasis [19] and is a
predictor of poor prognosis in different tumors [20–24]. Few studies
have reported on E-cadherin expression in SGC, but expression in SDC
and its prognostic value is unknown [25–27].
Prostate-specific membrane antigen (PSMA) expression in tumor
cells or tumor-associated neovasculature may also be prognostic factors
in SDC. We recently conducted a phase 2 imaging study using Gallium-
68-PSMA-PET/CT in 10 SDC patients, in which we found relevant
PSMA-ligand uptake (tumor/liver ratio > 1) in 4 patients. With im-
munohistochemistry, PSMA expression in tumor cells was positive in 5
patients, and PSMA expression in the tumor-associated neovasculature
was positive in 8 patients, but Gallium-68-PSMA uptake could not be
predicted with immunohistochemistry. In prostate cancer, high PSMA
tumor expression is an independent predictor of recurrence [28]. PSMA
expression in the tumor-associated neovasculature is a poor prognostic
factor in oral squamous cell carcinoma, renal cell carcinoma, and he-
patocellular carcinoma, whereas it has no prognostic value in gastric
and colorectal cancer, and is a favorable prognostic factor in medullary
thyroid carcinoma [29–33].
The aim of this study was to evaluate the prognostic value of c-MET,
E-cadherin, and tumor and neovascular PSMA expression in a cohort of
SDC patients. Furthermore, we evaluated whether these factors asso-
ciated with lymph node status, AR, and HER2 expression.
Material and methods
Patients
Tissue block from patients diagnosed with SDC in the Netherlands
between 1990 and 2014 were anonymously collected by use of the
Nationwide Network and Registry of Histo- and Cytopathology
(PALGA) [34]. In total 177 patients were included [1]. This cohort was
expanded by 25 SDC patients visiting the Radboud university medical
center, a referral center for SGC patients in the Netherlands, between
2014 and 2018. An expert SGC pathologist reviewed all tumors to
confirm the diagnosis. Of these 202 patients, sufficient primary tumor
material for construction of TMAs was available for 165 patients. A flow
chart of patient selection and analyses is shown in Fig. 1.
Clinical data
Clinical data were collected from the medical records. A no-objec-
tion system was used for secondary use of human tissue and medical
data in accordance to the code of conduct of the Federation of Dutch
Medical Scientific Societies (Human tissue and medical research: Code
of conduct for responsible use). For all patients who were alive at the
Fig. 1. Flow chart of patient selection and
study procedures. Abbreviations: AR: an-
drogen receptor. E-cadherin: epithelial cad-
herin. FISH: Fluorescence in situ hybridiza-
tion. HER2: Human epidermal growth factor
receptor 2. IHC: Immunohistochemistry.
PALGA: nationwide network and registry of
histo- and cytopathology in the Netherlands.
PSMA: prostate-specific membrane antigen.
Radboudumc: Radboud university medical
center, Nijmegen, the Netherlands. SDC:
salivary duct carcinoma. TMA: tissue mi-
croarray. 1 Boon E et al. Int j cancer
2018;143:758–66.
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start of this study, written informed consent was obtained. This study
was approved by the local medical ethical committee.
TMA construction
Formalin-fixed paraffin-embedded (FFPE) tumor blocks and hema-
toxylin and eosin (H&E) stained slides were requested from all patients.
From each FFPE tumor block, one to three (depending on tumor size)
2mm cores of the primary tumor were transferred into a TMA block,
using the TMA Grand Master (Sysmex). From these TMA blocks, slides
were cut for immunohistochemical analyses.
Immunohistochemistry
Androgen receptor
A rabbit monoclonal antibody against the androgen receptor was
used (EP120; Cell Marque) at a dilution of 1:200. Androgen receptor
staining was evaluated considering the staining intensity (0= negative,
1=weak, 2=moderate, 3= strong) as well as the percentage of po-
sitive nuclei (staining extent: 0=<10%, 1=≥10 to<30%, 2=≥30
to< 70%, 3=≥70%). The final (semi-quantitative) staining score was
recorded as the sum of the staining intensity and the staining extent, in
which 0 was regarded as negative,> 0 to<6 as low expression and 6
as high expression [35].
c-MET
A rabbit monoclonal IgG antibody targeting the C-terminus of
human MET (D1C2; Cell Signaling) was used. Staining intensity was
evaluated semi-quantitatively (negative, weak, moderate, strong) for
cytoplasmic and membranous immunoreactivity [36]. For the statistical
analysis, negative and weak staining were regarded as negative, and
moderate and strong staining were regarded as positive.
E-cadherin
A mouse monoclonal antibody against E-cadherin (SPM471;
Diagnostic Biosystems) was used at a dilution of 1:300 [37]. E-cadherin
was scored negative, intermediate or positive. In case of discrepancies
between different TMA cores of one tumor, the tumor was scored as
intermediate.
PSMA
A mouse antihuman PSMA monoclonal antibody (3E6; DAKO) di-
rected against the internal domain of the PSMA was used at a dilution of
1:80 [38]. For the tumor cells, PSMA staining was classified according
to the percentage of positive tumor cells as negative (0–10%), low
(positivity of 10–40%), moderate (positivity of 40–70%) and high
(positivity of> 70%). The intensity of the staining was scored ac-
cording to a semi-quantitative 4 grade scale (0=no staining, 1= low,
2=moderate, 3= high intensity) [39]. PSMA staining in the tumor-
associated neovasculature was scored as the number of PSMA-positive
vessels in the core [33].
HER2 assessment
HER2 expression was determined by ERBB2 fluorescent in situ hy-
bridization (FISH) according to standard ISH protocol using the ERBB2
probe of Kreatech (KI-10701, mapping 17q12). Scoring was performed
according to breast cancer guidelines of the American Society of
Clinical Oncology (ASCO) and the College of American Pathologists
(CAP) [40]. In case of an inconclusive ISH results, HER2 IHC was de-
termined using the polyclonal rabbit antihuman c-erbB-2 antibody of
DAKO according to protocol [40].
Data analysis
Descriptive statistics were used for patient and tumor
characteristics, including the expression levels of AR, HER2 and the
potential prognostic factors c-MET, E-cadherin, and PSMA expression in
tumor cells and neovasculature. For association with lymph node me-
tastases, AR, and HER2 expression, survival analyses, and Cox regres-
sion analyses, the potential prognostic factors were dichotomized: cy-
toplasmic c-MET, membranous c-MET, combined c-MET, and HER2
were scored negative versus positive, E-cadherin was scored negative/
intermediate versus positive, PSMA tumor expression was scored<4
versus ≥4 (=moderate intensity and extent), and PSMA neovascular
expression was scored<19.25 versus ≥19.25 (=median value).
All potential prognostic factors were tested for differences in N-
stage, the absolute number of tumor-positive lymph nodes, the lymph
node ratio (number of tumor-positive lymph nodes divided by total
number of lymph nodes in the neck dissection), and semi-quantitative
scored AR expression using the Mann-Whitney test, and tested for dif-
ferences in HER2 expression using the chi-square test. Difference in
PSMA tumor and neovascular expression in men and women were also
tested with the Mann-Whitney test.
Patients with distant metastatic disease at diagnosis (n=3) were
omitted from the prognostic factor analysis. Kaplan-Meier survival
curves and log-rank tests were used to test for differences in disease-free
survival (DFS) and OS for all potential prognostic factors. Univariable
Cox proportional hazard regression models were fitted for relevant
clinical and pathological factors (age, gender, ex-pleomorphic ade-
noma, T-stage, N-stage, absolute number of tumor-positive lymph
nodes, lymph node ratio, resection margins, primary tumor site, semi-
quantitative AR, HER2) and for the potential prognostic factors (c-MET,
E-cadherin, PSMA expression in tumor cells and neovasculature).
Second, a multivariable analysis was performed with a forward selec-
tion procedure based on the Wald test at significance level of 0.05.
Patients with missing values in one or more of the variables were ex-
cluded from the multivariable analysis. Analysis were performed using
SPSS version 25.0 (IBM).
Data availability
The data that support the findings of this study are available from
the corresponding author upon reasonable request.
Results
Patient characteristics
In this study, 165 patients diagnosed with SDC were included.
Median age at diagnosis was 65 years (range 36–92 years) and the male
to female ratio was 2.5:1. Of the 163 patients who received primary
treatment with curative intent, all but one patient received a primary
tumor resection, 129 patients underwent a neck dissection (79%), and
149 patients received postoperative radiotherapy (90%). The number of
tumor-positive lymph nodes was 0 in 53 patients (32%), 1–2 in 23
patients (14%), 3–15 in 51 patients (31%),> 15 in 32 patients (19%),
and missing in 6 patients (5%). The lymph node ratio could be calcu-
lated in 124 neck dissection specimens only.In the rest of the patients
the total number of removed lymph nodes was unknown and therefore
no ratio could be calculated. It was< 0.20 in 62 patients (50%) and
≥0.20 in 62 patients (50%). AR was negative in 8 patients (5%), ex-
pression was low in 87 patients (54%), and strong in 66 patients (41%).
HER2 was overexpressed in 47 patients (29%). Patient and tumor
characteristics are listed in Table 1.
Protein expression of c-MET, E-cadherin and PSMA
Immunohistochemical staining results are shown in Table 2 and
typical staining patterns are shown in supplementary figure 1. Cyto-
plasmic c-MET expression was present in 67 tumors (42%), membra-
nous c-MET expression in 29 tumors (18%), and cytoplasmic and/or
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membranous expression in 71 tumors (45%). E-cadherin loss was seen
in 7 tumors (4%) and intermediate E-cadherin expression in 14 tumors
(9%). PSMA tumor cell expression was moderate in 29 tumors (18%)
and negative/weak in the other tumors. The mean intensity of PSMA
tumor staining was 0.55 ± 0.65 and the mean staining extent was
25.7 ± 31.0%. PSMA expression in the tumor-associated neovascu-
lature was seen in 151 patients (96%).
Associations
Associations of all potential prognostic factors with lymph node
status, AR and HER2 expression, DFS and OS are shown in Table 3.
Regarding the lymph node status, we found that high PSMA tumor
expression (sum-score≥ 4) was significantly associated with a lower N-
stage (P=0.001), lower number of lymph node metastases
(P=0.018), and lower lymph node ratio (P=0.010). Membranous c-
MET expression was significantly associated with a lower N-stage
(P=0.040), but not with the number of tumor-positive lymph nodes or
lymph node ratio. The other factors were not significantly associated
with lymph node status.
Association of the potential prognostic factors with semi-quantita-
tively scored AR expression, showed that a high PSMA tumor expres-
sion (sum-score ≥4) and E-cadherin loss were significantly associated
with strong and weak AR expression, respectively (P=0.033 and
P=0.007). None of the factors were associated with HER2 expression.
Difference in PSMA tumor and neovascular expression in men and
women showed a significantly higher PSMA tumor expression in
women with a PSMA tumor sum-score of 2.0 ± 1.7 versus 1.4 ± 1.7
in men (P=0.029). PSMA neovascular expression did not significantly
Table 1
Patient and tumor characteristics.
Characteristics Number of patients (n = 165)
Age at diagnosis, in years, n (%)
• ≤50 18 (11%)
• 51–60 41 (25%)
• 61–70 52 (32%)
• 71–80 35 (21%)
• > 80 19 (12%)
Gender, n (%)
• Male 119 (72%)
• Female 46 (28%)
Carcinoma ex pleomorphic adenoma, n (%)
• Yes 67 (41%)
• No (“de novo”) 98 (59%)
Primary tumor, n (%)
• Parotid gland 138 (84%)
• Submandibular gland 17 (10%)
• Sublingual gland 1 (1%)
• Other
○ Minor salivary glands 7 (4%)
○ Lacrimal gland 1 (1%)
○ Unknown 1 (1%)
TNM stadium, n (%)
• T1/T2/T3/T4/Tx (%) 30 (18%)/49 (30%)/19 (12%)/59
(36%)/8 (5%)
• N0/N1/N2/N3/Nx (%) 53 (32%)/15 (9%)/96 (58%)/0
(0%)/1 (1%)
• M0/M1 (%) 162 (98%)/3 (2%)
Number of tumor-positive lymph nodes, n
(%)
• 0 53 (32%)
• 1–2 23 (14%)
• 3–15 51 (31%)
• > 15 32 (19%)
• Missing 6 (5%)
Lymph node ratio*, n (%)
• < 0.20 62 (50%)
• ≥0.20 62 (50%)
Overall stage, n (%)
• I/II/III/IVa-b/IVc/unknown (%) 15 (9%)/18 (11%)/13 (8%)/113
(70%)/3 (2%)/3(2%)
Primary treatment with curative intent (n=
163)
• Tumor resection + ND 128 (79%)
• Tumor resection without ND 33 (20%)
• Only ND 1 (1%)
• Lacrimal gland resection 1 (1%)
Postoperative radiotherapy, n (%)
• Yes 149 (90%)
• No 16 (10%)
AR expression1
• Negative 8 (5%)
• Low (> 0 <6) 87 (54%)
• Strong (=6) 66 (41%)
HER2 expression
• Negative 113 (71%)
• Positive 47 (29%)
Abbreviations: AR: Androgen receptor. HER2: Human epidermal growth factor
receptor 2. ND: neck dissection.
* Number of tumor-positive lymph nodes divided by total number of lymph
nodes in the neck dissection.
1 Locati et al., Head & neck 2016;38:724–31.
Table 2
Protein expression patterns.
Proteins Patients: n (%)
c-MET
Cytoplasmic c-MET expression
• Negative 91 (58%)
• Positive 67 (42%)
Membranous c-MET expression
• Negative 129 (82%)
• Positive 29 (18%)
Combined c-MET expression
• No cytoplasmic or membranous expression 87 (55%)
• Cytoplasmic and/or membranous expression 71 (45%)
E-cadherin
• E-cadherin expression
• Negative 7 (4%)
• Intermediate 14 (9%)
• Positive 137 (87%)
PSMA
Intensity of PSMA tumor expression
• Negative (< 1) 105 (66%)
• Weak (≥1 <2) 42 (26%)
• Moderate (≥2 <3) 13 (8%)
• Strong (3) 0 (0%)
Extent of PSMA tumor expression
• Negative (0–10%) 78 (49%)
• Low (10–40%) 30 (19%)
• Moderate (40–70%) 25 (16%)
• Strong (> 70%) 27 (17%)
PSMA tumor expression, sum-score1
• Negative (< 2) 100 (63%)
• Weak (≥2 <4) 31 (19%)
• Moderate (≥4 <6) 29 (18%)
• Strong (6) 0 (0%)
PSMA neovascular expression
• Negative (0 positive vessels) 7 (4%)
• Weak (< 19.25 positive vessels) 72 (46%)
• Strong (> 19.25 positive vessels) 79 (50%)
Abbreviations: E-cadherin: Epithelial cadherin. PSMA: Prostate-specific mem-
brane antigen.
1 The PSMA tumor sum-score was calculated by adding up staining intensity
(0–3) and staining extent (0–3).
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differ between women and men (28.9 ± 30.2 positive vessels vs.
24.3 ± 22.5, P=0.646).
Kaplan Meier survival curves showed a significantly longer OS
(P=0.022) and a trend towards a longer DFS (P=0.094) for patients
with high PSMA tumor expression versus low PSMA tumor expression
(Fig. 2). The other factors were not significantly associated with DFS or
OS (supplementary figure 2).
Cox regression analyses
In the univariable Cox regression analyses, high age at diagnosis,
high N-stage, high number of tumor-positive lymph nodes, high lymph
node ratio, and low PSMA tumor expression were associated with poor
OS. In the multivariable analysis, patients with a missing value in any
variable were not included, resulting in the inclusion of 135 patients.
The multivariable model only contained a high number of tumor-po-
sitive lymph nodes and high age at diagnosis. The results of the uni-
variable and multivariable models are shown in Table 4.
Discussion
In this study, we evaluated whether expression of c-MET, E-cad-
herin, and tumor or neovascular PSMA expression are prognostic fac-
tors for SDC using Kaplan-Meier survival curves, univariable and mul-
tivariable Cox regression analyses. Patients with high PSMA tumor
expression showed a significantly longer OS, trend towards a longer
DFS, and significantly reduced hazard ratio for death in the univariable
Cox regression analysis. It was not an independent variable for overall
survival in the multivariable model, in which only a high number of
tumor-positive lymph nodes and high age at diagnosis (> 80 years)
were independent variables for poor OS.
High PSMA tumor expression may be associated with survival in the
Kaplan-Meier and univariable Cox regression analysis because it is
significantly associated with a lower number of tumor-positive lymph
nodes, which is an independent poor prognostic factor in the multi-
variable analysis. In prostate cancer, high PSMA expression is not as-
sociated with lymph node status [41]. High PSMA tumor expression
was also significantly associated with high AR expression. Therefore,
the longer survival might be caused by better responses to ADT, al-
though AR protein expression is not a significant predictive factor of
clinical benefit from ADT in SDC [42]. Compared to prostate cancer
tumors, PSMA tumor expression is rather low. Mean PSMA tumor in-
tensity was 0.55 ± 0.65 and mean PSMA tumor extent was
25.7 ± 31.0% in SDCs, compared to 2.33 ± 1.11 and 67.8 ± 28.0%
in primary prostate cancers [39]. Finally, PSMA expression in tumor
cells was significantly higher in women versus men. In prostate cancer
patients, ADT results in increased PSMA expression [43]. In line with
this, it is possible that the physiological lower levels of androgen in
women result in higher expression levels of PSMA in women.
Remarkably, membranous c-MET expression was significantly as-
sociated with a lower N-stage, which is opposed to our hypothesis that
activation of the HGF/MET signaling pathway may be a causal factor of
lymph node metastases. However, membranous c-MET was not asso-
ciated with the other nodal scores, nor was cytoplasmic c-MET ex-
pression. Finally, we found an association between E-cadherin loss and
weak AR expression. One may wonder whether SDC tumor cells with a
high metastatic potential loose E-cadherin expression and AR expres-
sion, but Xu et al. showed a high prevalence of AR expression in me-
tastatic tumors (93%), and concordance between in the primary tumor
and metastatic tumor in 95% [44].
Although the studied markers do not seem to be independent
prognostic factors, they might serve as therapeutic targets. c-MET ex-
pressing tumors may be targeted with c-MET inhibitors like the multi-
target tyrosine kinase inhibitor crizotinib or cabozantinib. Therefore,
we performed a phase 2 clinical trial on the efficacy of cabozantinib in
c-MET positive SGC. Unfortunately, this trial was closed prematurely
because of severe wound and fistula complications in 32% of patients
[45]. Loss of E-cadherin is not an established druggable target, but
preclinical data indicate that E-cadherin deficient cancers depend upon
ROS1 signaling. Therefore, ROS1 inhibitors such as the tyrosine kinase
inhibitor crizotinib or entrectinib may be effective in E-cadherin defi-
cient cancers [46]. PSMA is an important target for imaging and
radionuclide therapy in castration-resistant prostate cancer (CRPC)
patients, and may be used for these purposes in SDC. Our recently
Table 3
Association of potential prognostics factors with lymph node status, AR expression, HER2 expression, disease-free survival (DFS) and overall survival (OS).
Significant results are depicted in bold.
N-stage No. of tumor-positive
lymph nodes
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(p= 0.731)
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P=0.265 22 vs. 24 mo.
(p= 0.435)
44 vs. 52 mo.
(p=0.848)
PSMA tumor sum-score
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P= 0.150 23 vs. 25 mo.
(p= 0.686)
70 vs. 48 mo.
(p=0.312)
HER2 expression









n.a. 24 vs. 23 mo.
(p= 0.553)
60 vs. 47 mo.
(p=0.678)
1 Locati et al., Head & neck 2016;38:724–31.
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conducted study on PSMA-PET/CT in 10 SDC patients indeed showed
relevant PSMA-ligand uptake in 40% of patients [47].
A strength of this study is the use of a large number of tumor
samples of this rare cancer, and the availability of relevant clinical and
pathological characteristics, which allowed us to analyze the prognostic
value in a multivariable analysis. A limitation of this study is that we
used TMA’s for immunohistochemical staining, which have a risk of
sampling error. We tried to avoid this by taking 2–3 cores of every
primary tumor whenever possible [48]. Furthermore, no correction for
multiple testing was performed, because this was an explorative study.
In conclusion, c-MET, E-cadherin, PSMA tumor expression, and
PSMA neovascular expression are no independent prognostic factors in
this cohort of SDC patients. Nevertheless, these markers may be ther-
apeutic targets.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Fig. 2. Kaplan-Meier survival curves of overall survival (A) and disease-free
survival (B) in patients with high (≥4) versus low (<4) PSMA expression in
the tumor cells.
Table 4
Univariable and multivariable Cox regression analyses for overall survival.
Univariable Cox regression analyses
Factor No. of
patients
HR (95% CI) P
Age at diagnosis 0.075
• ≤50 18 1.00 –
• 51–60 40 2.28 (0.92–5.62) 0.075
• 61–70 51 1.55 (0.62–3.87) 0.346
• 71–80 34 1.90 (0.74–4.86) 0.180
• > 80 19 3.83 (1.39–10.59) 0.010
Gender
• Male 116 1.00 –
• Female 46 1.58 (0.91–2.75) 0.105
Carcinoma ex pleomorphic
adenoma
• No (“de novo”) 98 1.00 –
• Yes 67 1.00 (0.63–1.57) 0.99
T-stadium
• T1/T2 79 1.00 –
• T3/T4 76 1.29 (0.80–2.07) 0.292
N-stadium 0.034
• N0 53 1.00 –
• N1 15 1.34 (0.56–3.21) 0.511
• N2 93 1.98 (1.15–3.41) 0.014
• N3 0 – –
Number of positive lymph nodes 0.007
• 0 53 1.00 –
• 1–2 23 0.79 (0.35–1.80) 0.575
• 3–15 51 1.67 (0.93–3.00) 0.086
• > 15 31 2.67 (1.40–5.10) 0.003
Lymph node ratio1
• < 0.20 62 1.00 –
• > 0.20 61 2.06 (1.21–3.52) 0.008
Resection margins 0.139
• Free 13 1.00 –
• Close 20 0.48 (0.15–1.52) 0.212
• Tumor-positive margins 126 1.10 (0.50–2.40) 0.819
Primary tumor site 0.765
• Parotid gland 135 1.00 –
• Submandibular gland 17 0.87 (0.41–1.83) 0.711
• Other 9 1.34 (0.53–3.34) 0.536
Semiquantitative AR staining 0.648
• Negative 8 1.00 –
• Low (> 0 <6) 85 0.67 (0.28–1.60) 0.367
• Strong (=6) 65 0.65 (0.27–1.56) 0.331
HER2
• Negative 111 1.00 –
• Positive 46 1.11 (0.67–1.84) 0.681
Cytoplasmic C-met expression
• Negative 89 1.00 –
• Positive 66 0.95 (0.59–1.54) 0.837
Membranous C-met expression
• Negative 127 1.00 –
• Positive 28 0.85 (0.44–1.62) 0.610
Combined c-MET expression
• Negative 85 1.00 –
• Positive 70 0.96 (0.59–1.55) 0.855
E-cadherin 0.301
• Negative 7 1.00 –
• Intermediate 13 4.01 (0.50–32.18) 0.191
• Positive 135 3.00 (0.42–21.67) 0.276
PSMA tumor staining
• Negative (score < 4) 128 –
• Positive (score ≥4) 29 0.45 (0.22–0.94) 0.034
PSMA neovascular staining
• Weak (< 19.25) 78 1.00 –
• Strong (≥19.25) 77 1.25 (0.78–2.00) 0.360
(continued on next page)
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.oraloncology.2020.105018.
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